Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | HASPIN | Q8TF76 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122972 | 1.00 | DYRK1A (0.55) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL20123007 | 0.85 | DYRK1A (0.58) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL30664315 | 0.85 | DYRK1A (0.58) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL20122960 | 0.81 | DYRK1A (0.45) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL30664227 | 0.81 | DYRK1A (0.45) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL20122936 | 0.79 | AURKA (0.41) | DYRK1AMAOAACHEBCHE | |
| SCHEMBL20123059 | 0.78 | HASPIN (0.43) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL30664168 | 0.78 | HASPIN (0.43) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL20122851 | 0.76 | DYRK1A (0.47) | DYRK1AMAOAACHEBCHEHASPIN | |
| SCHEMBL28654194 | 0.75 | ACHE (0.80) | DYRK1AMAOAACHEBCHEHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | claimed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | DYRK1A 498/4885MAOA 246/4885ACHE 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.